| Drug Name |
Ezogabine |
| Drug ID |
BADD_D00865 |
| Description |
Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy. FDA approved in June 10, 2011 under the name of ezogabine. |
| Indications and Usage |
Adjuvant treatment of partial-onset seizures. |
| Marketing Status |
approved; investigational |
| ATC Code |
N03AX21 |
| DrugBank ID |
DB04953
|
| KEGG ID |
D09569
|
| MeSH ID |
C101866
|
| PubChem ID |
121892
|
| TTD Drug ID |
D0X7GL
|
| NDC Product Code |
Not Available |
| UNII |
12G01I6BBU
|
| Synonyms |
ezogabine | retigabine | N-(2-amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester | D 20443 | D-20443 | Potiga | D 23129 | D-23129 | ethyl N-(2-amino-4-(4-fluorobenzylamino)phenyl)carbamate hydrochloride |
